AKT inhibitors however may be helpful in patients with BRAFV600E melanomas as Akt activation has been shown to cooperate with the mutant B-Raf to promote progression and chemoresistance (Tran et al., 2008; Shao and Aplin, 2010). Here, AKT1 is linked to melanoma.